Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 16Radiotherapy 11Lomustine 8Carmustine 6Vincristine 5Procarbazine 5Etoposide 3Corticotropin-Releasing Hormone 3Carboplatin 3vorasidenib 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Isotretinoin 2Everolimus 2Dihematoporphyrin Ether 2Cisplatin 2Chemotherapy, Adjuvant 2etoposide phosphate 1carmustine, poliferprosan 20 drug combination 1Valproic Acid 1Tranexamic Acid 1Trabedersen 1Thioguanine 1Surgical Procedures, Operative 1Semustine 1Radiotherapy, Conformal 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Astrocytoma × Semustine × Clear all
NCT00335075 2017-05-15

Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)

Merck Sharp & Dohme LLC

Phase 3 Completed
151 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡